InspireMD, Inc. (NSPR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

InspireMD, Inc. (NSPR) Healthcare & Pipeline Overview

InspireMD, Inc. focuses on developing and commercializing its MicroNet stent platform, offering solutions like CGuard and MGuard Prime for vascular and coronary diseases. Operating in Europe, Latin America, the Middle East, and Asia Pacific, the company addresses critical needs in embolic protection within the medical device sector.

What Is the Investment Thesis for NSPR?

InspireMD operates in a niche segment of the medical device industry, focusing on embolic protection systems. With a market capitalization of $42.2M, the company's financial performance reflects a high-risk, high-reward profile, indicated by a negative profit margin of -344.1% and a gross margin of 28.1%. Key value drivers include the continued adoption of CGuard and MGuard Prime in international markets and the successful development and commercialization of PVGuard. Growth catalysts involve expanding distribution networks and securing regulatory approvals in new territories. Potential risks include the company's ability to manage its cash flow, compete with larger medical device companies, and navigate regulatory hurdles. The company's beta of 0.94 suggests a market risk level close to the overall market.

Based on FMP financials and quantitative analysis

NSPR Key Highlights

Market Cap of $42.2M indicates a small-cap company with potential for growth but also higher volatility.

• Gross Margin of 28.1% suggests the company retains a portion of revenue after accounting for the cost of goods sold, but this needs to cover operating expenses.
• Profit Margin of -344.1% highlights significant losses, indicating the company's expenses far exceed its revenue.
• Beta of 0.94 suggests the stock's volatility is similar to the overall market.
• The company focuses on international markets, particularly Europe, Latin America, the Middle East, and Asia Pacific, indicating a global strategy.

Who Are NSPR's Competitors?

NSPR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NSPR's Key Strengths?

Proprietary MicroNet stent platform technology.

• Specialized product portfolio for embolic protection.
• Established presence in Europe, Latin America, the Middle East, and Asia Pacific.
• Focus on innovative solutions for vascular and coronary diseases.

What Are NSPR's Weaknesses?

Negative profit margin indicates financial instability.

• Small market capitalization limits resources for expansion.
• Reliance on distributors for sales and marketing.
• Limited product diversification.

What Could Drive NSPR Stock Higher?

Regulatory approvals for PVGuard in key markets.

• Expansion of distribution network in existing and new territories.
• Clinical studies demonstrating the efficacy and safety of CGuard and MGuard Prime.

What Are the Key Risks for NSPR?

Financial-distress signal — its Altman Z-Score of -10.28 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-81.5%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Competition from larger medical device companies with greater resources.
• Regulatory hurdles and delays in obtaining approvals.
• Negative profit margin and need for additional financing.
• Product liability risks and potential lawsuits.

What Are the Growth Opportunities for NSPR?

• Expansion into New Geographic Markets: InspireMD has the opportunity to expand its market presence beyond its current focus on Europe, Latin America, the Middle East, and Asia Pacific. Entering new markets, such as North America, could significantly increase its revenue potential. The global market for embolic protection devices is estimated to reach $2.5 billion by 2028, providing a substantial opportunity for InspireMD to capture additional market share through strategic expansion.
• Development and Commercialization of PVGuard: The successful development and commercialization of PVGuard, a MicroNet mesh sleeve and self-expandable stent for peripheral vascular applications, represents a significant growth opportunity. The market for peripheral vascular interventions is growing due to the increasing prevalence of peripheral artery disease (PAD). The global PAD market is projected to reach $8 billion by 2027, offering a substantial market for PVGuard.
• Strategic Partnerships and Distribution Agreements: Forming strategic partnerships with larger medical device companies or establishing distribution agreements with established distributors can accelerate InspireMD's market penetration and increase sales. Collaborating with partners who have established relationships with hospitals and physicians can provide access to new customers and markets. The medical device distribution market is highly fragmented, offering numerous opportunities for strategic alliances.
• Increased Adoption of CGuard and MGuard Prime: Driving increased adoption of its existing products, CGuard and MGuard Prime, remains a key growth opportunity. This can be achieved through targeted marketing campaigns, physician education programs, and clinical studies demonstrating the efficacy and safety of these devices. The market for carotid artery stenting and acute coronary syndrome interventions is growing, driven by an aging population and increasing awareness of cardiovascular disease.
• Innovation and Product Development: Continued investment in research and development to innovate and develop new products based on the MicroNet stent platform is crucial for long-term growth. This includes exploring new applications for the technology and developing next-generation devices with improved performance and features. The medical device industry is characterized by rapid technological advancements, making innovation a key driver of competitive advantage.

What Are NSPR's Competitive Advantages?

• Proprietary MicroNet stent platform technology.
• Focus on embolic protection systems.
• Established presence in international markets.
• Specialized product portfolio targeting specific vascular and coronary diseases.

What Does NSPR Do?

Founded in 2005 and headquartered in Tel Aviv-Yafo, Israel, InspireMD, Inc. is a medical device company dedicated to the development and commercialization of its proprietary MicroNet stent platform technology. The company's core focus is on providing innovative solutions for the treatment of vascular and coronary diseases. InspireMD's primary products include the CGuard carotid embolic prevention system, designed for use in carotid artery applications, and the MGuard Prime embolic protection system, intended for patients with acute coronary syndromes, such as acute myocardial infarction, saphenous vein graft coronary interventions, and bypass surgery. Additionally, InspireMD is actively developing PVGuard, a MicroNet mesh sleeve and self-expandable stent aimed at peripheral vascular applications. These products are distributed through local partners in Europe, Latin America, the Middle East, and the Asia Pacific regions. The company's technology aims to improve patient outcomes by reducing the risk of embolization during critical vascular procedures, addressing a significant need in the medical community.

What Products and Services Does NSPR Offer?

• Develops MicroNet stent platform technology.
• Commercializes embolic prevention systems.
• Offers CGuard for carotid artery applications.
• Provides MGuard Prime for acute coronary syndromes.
• Develops PVGuard for peripheral vascular applications.
• Sells products through local distributors in Europe, Latin America, the Middle East, and Asia Pacific.

How Does NSPR Make Money?

• Develops and manufactures medical devices.
• Sells products through distributors.
• Focuses on vascular and coronary disease treatments.
• Generates revenue from product sales in international markets.

What Industry Does NSPR Operate In?

InspireMD operates within the medical device industry, specifically targeting the vascular and coronary disease segments. The market for embolic protection systems is driven by the increasing prevalence of cardiovascular diseases and the growing demand for minimally invasive procedures. The industry is characterized by intense competition, with larger players like Boston Scientific and Medtronic dominating the market. InspireMD's success depends on its ability to differentiate its MicroNet stent platform and secure regulatory approvals in key markets. The global medical device market is projected to reach $600 billion by 2026, presenting significant opportunities for growth.

Who Are NSPR's Key Customers?

• Hospitals and medical centers.
• Interventional cardiologists.
• Vascular surgeons.
• Patients with vascular and coronary diseases.

Over the past six months, InspireMD, Inc. insiders filed 12 SEC Form 4 transactions — 1 sales and 11 purchases. On net that is roughly 296K shares acquired (about $343K) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: InspireMD, Inc.

Revenue for InspireMD, Inc. came in at $1.8M during Q2 2026, a 47.9% contraction versus the preceding quarter. The company recorded a net loss of $14.3M, with diluted EPS of $-0.19. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, NSPR averaged $-0.12 in diluted EPS.

NSPR Valuation & Market Position

With a $42.2M market cap, InspireMD, Inc. sits in the micro-cap segment of the market. Relative to its peer group, NSPR's quantitative score of 17/100 is below the peer average of 69/100.

Return on equity for InspireMD, Inc. stands at -81.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -66.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -99.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.15 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -59.1%, the inverse of the P/E and a quick read on earnings relative to price.

InspireMD, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -10.28 places it in the distress zone, a signal of elevated financial risk.

InspireMD, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 6.8% above estimates on average.

Wall Street analysts project InspireMD, Inc. revenue of about $9.8M for fiscal 2026, with EPS near $-0.61.

Company Profile

InspireMD, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Miami, US. The company is led by CEO Marvin L. Slosman. NSPR has traded publicly since 2011.

NSPR Financials

NSPR Latest News

NSPR Analyst Consensus

NSPR MoonshotScore

What Investors Ask About InspireMD, Inc. (NSPR) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources